Brind.

Xilio Therapeutics is advancing its drug candidate XTX301 in partnership with Gilead Sciences.

1 report, 1 independent Updated Aug 14

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Xilio Therapeutics (United States)Gilead Sciences

Keep exploring

The entities involved

Xilio Therapeutics (United States)
organization
- Xilio Therapeutics shares underperformed the S&P 500 so far this year, based on events of August 14, 2025.09:25
Gilead Sciences
American company

Nothing else this week.

Coverage

Newest first; wire copies grouped

Aug 14GlobeNewswireXilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2025 Financial Results Announced updated Phase 2 data at ASCO for vilastobart, a tumor-activated, Fc-enhanced, anti-CTLA-